News & Events
- Seed Health Joins Microbiome Therapeutics Innovation Group
- Rebiotix Leaders to Discuss Microbiome Product Development Challenges and Regulation at Microbiome Movement – Drug Development Summit 2019
- Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study
- Vedanta Biosciences’ Silvia Caballero, Ph.D., Named as an MIT Technology Review Global Innovator Under 35
- Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration Safety Alert Related to Use of Fecal Microbiota Transplantation
- Microbiome Therapeutics Innovation Group Statement on FDA Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms
- Seres Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
- Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
- Seres Therapeutics to Present at the Jefferies 2019 Healthcare Conference
- Microbiota Restoration Takes the Podium at DDW 2019: Investigational Microbiota-Based Therapies for Recurrent C. diff Highlighted
- Vedanta Biosciences Closes Extended $45.5 Million Series C Financing
- Vedanta Biosciences Key Microbiome Patent Upheld in European Opposition Proceedings
- Seres Therapeutics Reports First Quarter Financial Results and Provides Clinical Pipeline Progress Update
- Seres Therapeutics to Host First Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on May 2, 2019
- Seres Therapeutics Presents New Preclinical Data Supporting the Development of SER-401 for Immuno-Oncology at the 2019 American Association for Cancer Research Annual Meeting